T-Curx, a Würzburg-based biotech company, raised $20M in a Series A funding round led by BiomedVC to accelerate the development of its CAR-T therapies.
T-Curx, a Würzburg, Germany-based biotech company, raised $20M in Series A financing. The round was led by BiomedVC and included Bayern Kapital, HighLight Capital, and i&iBio Fund as additional investors. The company intends to use the funds to accelerate clinical development of its CAR-T therapies. T-Curx specializes in non-viral CAR-T technologies for scalable treatment solutions.
Who to call at T-Curx, and when
A new round usually means T-Curx is about to hire and buy. The teams that reach out first get the meeting.
An alert the day T-Curx raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at T-Curx, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
T-Curx
Location
Würzburg, Bayern, Germany
About
T-Curx is a Würzburg, Germany-based biotech company focused on developing next-generation CAR-T cell therapies manufactured using non-viral technologies. The company aims to provide effective cancer therapies for patients suffering from acute myeloid leukemia (AML) and solid tumors. T-Curx utilizes proprietary non-viral CAR-T technologies for scalable and cost-effective manufacturing of CAR-T cells. It was spun out from the University Clinics Würzburg and is led by Ulf Grawunder, PhD.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment T-Curx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WürzburgBiotechnologyHealth Care